Using donor-specific antibodies to monitor the need for immunosuppression

Transplantation

Volumn 93, Issue 11, 2012, Pages 1173-1178

  Hoshino, Junichi ^a,b   Kaneku, Hugo ^a   Everly, Matthew J ^c   Greenland, Sander ^b   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c One Lambda Inc   (United States)

Author keywords

Clonal deletion; Donor specific antibodies; Drug weaning; DSA monitoring; Transplantation

Indexed keywords

BORTEZOMIB; CALCINEURIN INHIBITOR; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; LIVING DONOR; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MONITORING, IMMUNOLOGIC; PREDNISONE; PROPORTIONAL HAZARDS MODELS; TRANSPLANTATION TOLERANCE;

EID: 84862296369     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824f3d7c     Document Type: Article

References (39)

1. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after renal transplantation: Current status and future challenges. Ann Surg 2010; 252: 915.
2. Sayegh MH, Remuzzi G. Clinical update: Immunosuppression minimisation. Lancet 2007; 369: 1676.
3. Vincenti F. Immunosuppression minimization: Current and future trends in transplant immunosuppression. J AmSoc Nephrol 2003; 14: 1940.
4. Hricik DE. Steroid-free immunosuppression in kidney transplantation: An editorial review. Am J Transplant 2002; 2: 19.
5. Mizutani K, Shibata L, Ozawa M, et al. Detection of HLA and MICA antibodies before kidney graft failure. Clin Transpl 2006; 255.
6. Ozawa M, Rebellato LM, Terasaki PI, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006; 265.
7. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962.
8. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
9. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
10. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560.
11. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
12. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
13. van de Wetering J, Gerrits JH, van Besouw NM, et al. Successful tapering of immunosuppression to low-dose monotherapy steroids after living-related human leukocyte antigen-identical renal transplantation. Transplantation 2009; 87: 740.
14. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231.
15. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012.
16. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73: 863.
17. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28: 478.
18. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008; 73: 465.
19. Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol 2009; 174: 1154.
20. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010; 28: 436.
21. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079.
22. Sanchez-Fructuoso AI, Santiago JL, Perez-Flores I, et al. De novo anti-HLA antibodies in renal allograft recipients: A cross-section study. Transplant Proc 2010; 42: 2874.
23. Lee PC, Zhu L, Terasaki PI, et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
24. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438.
25. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
26. Howell WM, Harmer A, Briggs D, et al. British Society for Histocompatibility & Immunogenetics and British Transplantation Society guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. Int J Immunogenet 2010; 37: 435.
27. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103.
28. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo antihuman leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010; 89: 178.
29. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
30. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319.
31. Ozawa M, Terasaki PI, Lee JH, et al. 14th International HLA and Immunogenetics Workshop: Report on the Prospective Chronic Rejection Project. Tissue Antigens 2007; 69(Suppl 1): 174.
32. Berga JK, Mateu LM, Catalan SB, et al. Donor-specific HLA antibodies: Risk factors and outcomes after kidney transplantation. Transplant Proc 2011; 43: 2154.
33. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106.
34. Kawai T, Benedict Cosimi A. Induction of tolerance in clinical kidney transplantation. Clin Transplant 2010; 24(Suppl 22): 2.
35. Trivedi HL, Kaneku H, Terasaki PI, et al. Clonal deletion using total lymphoid irradiation with no maintenance immunosuppression in renal allograft recipients. Clin Transpl 2009; 265.
36. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
37. Trivedi HL, Terasaki PI, Feroz A, et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010; 90: 221.
38. Greenland S. Model-based estimation of relative risks and other epidemiologicmeasures in studies of common outcomes and in casecontrol studies. Am J Epidemiol 2004; 160: 301.
39. Stata Version 10.1. College Station, TX, Stata Corporation, 2011.